Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 1999

Study Completion Date

September 30, 2001

Conditions
Pancreatic Cancer
Interventions
DRUG

gemcitabine hydrochloride

DRUG

tacedinaline

Trial Locations (16)

21225

Sinai Hospital of Baltimore, Baltimore

22031

Northern Virginia Oncology Group, Fairfax

27609

Raleigh Hematology/Oncology Associates - Wake Practice, Raleigh

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37203

Sarah Cannon-Minnie Pearl Cancer Center, Nashville

38117

West Clinic, P.C., Memphis

45236

Jewish Hospital of Cincinnati, Inc., Cincinnati

48073

William Beaumont Hospital, Royal Oak

75702

Tyler Cancer Center, Tyler

90048

Cedars-Sinai Comprehensive Cancer Center, Los Angeles

44106-5065

Ireland Cancer Center, Cleveland

R2H 2A6

St. Boniface General Hospital, Winnipeg

B3H 1V7

Nova Scotia Cancer Centre, Halifax

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

K1H 8L6

Ottawa Regional Cancer Center - General Division, Ottawa

H2L-4M1

Centre Hospitalier de l'Universite de Montreal, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00004861 - Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter